A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.

By Marilynn Larkin

NEW YORK (Reuters Health) – Measuring tumor-specific mutations in blood and urine samples may be useful for monitoring response to treatment and identifying early signs of metastases after radical cystectomy in patients with advanced bladder cancer, researchers in Denmark suggest.

A recent survey has revealed that precision medicine programs are gaining ground as a critical investment within oncology health care systems.
A recent study found that multiple factors including insurance status, ethnicity, and individual providing the diagnosis are associated with delays in treatment for patients with melanoma.
The pharmacy benefits manager Express Scripts has signaled its embrace of value-based care with its announced purchase of eviCore.
The US Food and Drug Administration has granted breakthrough therapy designation to an EGFR tyrosine kinase inhibitor for the first-line treatment of EGFR-positive non-small cell lung cancer.
The American Society of Clinical Oncology and Friends of Cancer Research recently released a joint recommendation to promote inclusiveness for cancer clinical trial enrollment criteria.
Patients with cancer receiving radiation therapy who have a previous psychiatric diagnosis have 208% higher follow-up emergency department costs than patients without a pre-existing psychiatric diagnosis.
Approximately 40% of patients with rheumatoid arthritis with persistent moderate to high disease activity waited at least 90 days for adjustment of their DMARD therapy.
A real-life analysis compared multiple antidiabetic medications for increased risk of heart failure hospitalization.